← Leaderboards
Nicholas Vogelzang
University Of Chicago
$347,270
Attributed
$347,270
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$12,949,391 · 7
By mechanism
P30$12,891,837 · 3
M01$57,554 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Chicago
Same institution · by research overlap
- Murray J Favus$423,464
- Robert L Rosenfield$3,734,702
- Daniel J Spergel$1,003,348
- Payal Tiwari$462,524
- Andrew M Wolfe$3,333,015
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman Therapy EvaluationNeoplasm /CancerHuman SubjectBiomedical FacilityAntineoplasticsProstate NeoplasmsNeoplasm /Cancer TherapyInhibitor /AntagonistNeoplasm /Cancer ChemotherapyMaleDrug Screening /EvaluationClinical Trial Phase IDiphosphonateBone DensityOsteoporosisSkeletal Disorder ChemotherapyAndrogensPharmacokineticsCancer PreventionEducation Evaluation /PlanningEndothelinGrowth FactorGrowth Inhibitors
Grant awards (20)
Zoledronate in Osteoporosis of Prostate Cancer$24,775
M01 · FY2004 · RR
UCCRC -Cancer Center Support Grant$3,716,017
P30 · FY2003 · CA
UCCRC -Cancer Center Support Grant$400,000
P30 · FY2003 · CA
UCCRC -Cancer Center Support Grant$3,602,038
P30 · FY2002 · CA
UCCRC -Cancer Center Support Grant$400,000
P30 · FY2002 · CA
CORE--DEVELOPMENTAL FUNDS$0
P30 · FY2002 · CA
PHARMACOKINETICS OF ABT-627 IN SUBJECTS WITH REFRACTORY MALIGNANCIES$0
M01 · FY2002 · RR
CORE--DEVELOPMENTAL FUNDS$0
P30 · FY2002 · CA
ZOLEDRONATE &OSTEOPOROTIC EFFECTS OF ANDROGEN DEPRIVATI$0
M01 · FY2002 · RR
UCCRC--CANCER CENTER SUPPORT GRANT$1,750,787
P30 · FY2001 · CA
UCCRC-Cancer Center Support Grant$266,581
P30 · FY2001 · CA
PROSTATE CANCER$0
P30 · FY2001 · CA
PROSTATE CANCER$0
P30 · FY2001 · CA
UCCRC--CANCER CENTER SUPPORT GRANT$2,466,698
P30 · FY2000 · CA
PROSTATE CANCER$289,716
P30 · FY2000 · CA
PHASE I STUDY OF CEP-2563 DIHYDROCHLORIDE IN ADULTS WITH SOLID TUMORS$32,779
M01 · FY2000 · RR
ZOLEDRONATE &OSTEOPOROTIC EFFECTS OF ANDROGEN DEPRIVATI$0
M01 · FY2000 · RR
PHARMACOKINETICS OF ABT-627 IN SUBJECTS WITH REFRACTORY MALIGNANCIES$0
M01 · FY2000 · RR
PHARMACOKINETICS OF ABT-627 IN SUBJECTS WITH REFRACTORY MALIGNANCIES$0
M01 · FY2000 · RR
ZOLEDRONATE &OSTEOPOROTIC EFFECTS OF ANDROGEN DEPRIVATI$0
M01 · FY2000 · RR